Heterotandem bicyclic peptide complex

Heterotandem bicyclic peptide complexes address the challenge of cancer treatment specificity by forming stable, targeted bindings to cancer cell markers and immune cell markers, enhancing therapeutic efficacy.

JP7876049B2Active Publication Date: 2026-06-18BICYCLETX LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2025185492
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-10-03
Filing Date
2025-11-04
Publication Date
2026-06-18
Estimated Expiration
2040-10-05

Smart Images

  • Figure 0007876049000001
    Figure 0007876049000001
  • Figure 0007876049000002
    Figure 0007876049000002
  • Figure 0007876049000003
    Figure 0007876049000003
Patent Text Reader

Abstract

The present invention provides a ligand that binds to Nectin-4 present on cancer cells, or a pharmaceutically acceptable salt thereof. The present invention relates to a heterotandem bicyclic peptide complex comprising a first peptide ligand that binds to a component present on a cancer cell conjugated via a linker to a second peptide ligand that binds to a component present on an immune cell, and to the use of the heterotandem bicyclic peptide complex in the prevention, suppression, or treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Method and composition

    JP2011514803A

  • EphA2-specific bicyclic peptide ligands

    JP2021506910A

  • Novel bispecific polypeptides against CD137

    WO2017182672A1

  • Bicyclic peptide ligands specific for CD137

    WO2019025811A1

  • Multimeric bicyclic peptide ligands

    WO2019162682A1